Suppr超能文献

尽管进行了酶替代疗法,法布病患者仍存在补体激活和细胞炎症。

Complement activation and cellular inflammation in Fabry disease patients despite enzyme replacement therapy.

机构信息

Institute for Systemic Inflammation Research, University of Lübeck, Lübeck, Germany.

Department of Internal Medicine D, University Hospital Münster, Münster, Germany.

出版信息

Front Immunol. 2024 Jan 18;15:1307558. doi: 10.3389/fimmu.2024.1307558. eCollection 2024.

Abstract

Defective α-galactosidase A (AGAL/GLA) due to missense or nonsense mutations in the gene results in accumulation of the glycosphingolipids globotriaosylceramide (Gb3) and its deacylated derivate globotriaosylsphingosine (lyso-Gb3) in cells and body fluids. The aberrant glycosphingolipid metabolism leads to a progressive lysosomal storage disorder, i. e. Fabry disease (FD), characterized by chronic inflammation leading to multiorgan damage. Enzyme replacement therapy (ERT) with agalsidase-alfa or -beta is one of the main treatment options facilitating cellular Gb3 clearance. Proteome studies have shown changes in complement proteins during ERT. However, the direct activation of the complement system during FD has not been explored. Here, we demonstrate strong activation of the complement system in 17 classical male FD patients with either missense or nonsense mutations before and after ERT as evidenced by high C3a and C5a serum levels. In contrast to the strong reduction of lyso-Gb3 under ERT, C3a and C5a markedly increased in FD patients with nonsense mutations, most of whom developed anti-drug antibodies (ADA), whereas FD patients with missense mutations, which were ADA-negative, showed heterogenous C3a and C5a serum levels under treatment. In addition to the complement activation, we found increased IL-6, IL-10 and TGF-ß1 serum levels in FD patients. This increase was most prominent in patients with missense mutations under ERT, most of whom developed mild nephropathy with decreased estimated glomerular filtration rate. Together, our findings demonstrate strong complement activation in FD independent of ERT therapy, especially in males with nonsense mutations and the development of ADAs. In addition, our data suggest kidney cell-associated production of cytokines, which have a strong potential to drive renal damage. Thus, chronic inflammation as a driver of organ damage in FD seems to proceed despite ERT and may prove useful as a target to cope with progressive organ damage.

摘要

由于基因中错义或无义突变导致α-半乳糖苷酶 A (AGAL/GLA) 缺陷,糖鞘脂类糖基神经酰胺 (Gb3) 及其去酰化衍生物糖基鞘氨醇 (lyso-Gb3) 在细胞和体液中积累。异常的糖鞘脂代谢导致进行性溶酶体贮积症,即法布里病 (FD),其特征为慢性炎症导致多器官损伤。用agalase-alfa 或 -beta 进行酶替代疗法 (ERT) 是促进细胞 Gb3 清除的主要治疗选择之一。蛋白质组学研究表明,在 ERT 过程中,补体蛋白发生变化。然而,FD 期间补体系统的直接激活尚未得到探索。在这里,我们证明了 17 名经典男性 FD 患者(携带错义或无义突变)在 ERT 前后补体系统均被强烈激活,这表现为血清 C3a 和 C5a 水平升高。与 ERT 下 lyso-Gb3 的显著减少相反,无义突变的 FD 患者的 C3a 和 C5a 明显增加,其中大多数患者产生了抗药物抗体 (ADA),而无义突变的 FD 患者 ADA 阴性,在治疗过程中表现出异质的 C3a 和 C5a 血清水平。除了补体激活,我们还发现 FD 患者的血清 IL-6、IL-10 和 TGF-β1 水平升高。在接受 ERT 的携带错义突变的患者中,这种增加最为明显,其中大多数患者患有轻度肾病,肾小球滤过率估计值降低。总之,我们的研究结果表明,FD 中补体的激活与 ERT 治疗无关,特别是在无义突变和 ADA 发展的男性中。此外,我们的数据表明肾脏细胞相关细胞因子的产生,这具有强烈的驱动肾脏损伤的潜力。因此,FD 中器官损伤的慢性炎症似乎在 ERT 后仍在继续,并可能作为应对进行性器官损伤的靶点证明是有用的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86f3/10830671/fa3aa50f586e/fimmu-15-1307558-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验